We suggest to use analysis of Cardiol Therapeutics fundamentals to see if markets are presently mispricing the company. We were able to break down and interpolate data for twenty-nine available fundamental indicators for Cardiol Therapeutics Class, which can be compared to its peers. The stock experiences a very speculative upward sentiment. Check odds of Cardiol Therapeutics to be traded at C$1.444 in 90 days. Key indicators impacting Cardiol Therapeutics' financial strength include:
Understanding current and past Cardiol Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cardiol Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Cardiol Therapeutics' assets may result in an increase in income on the income statement.
Cardiol Therapeutics competes with Avicanna, Medicenna Therapeutics, and Charlottes Web. Cardiol Therapeutics Inc., a biotechnology company, engages in the research and commercial development of proprietary drug formulations for the treatment of heart failure and cancer. The company was incorporated in 2017 and is headquartered in Oakville, Canada. CARDIOL THERAPEUTICS operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. It employs 6 people.
Foreign Associate
USA
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
You should never invest in Cardiol Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Cardiol Stock, because this is throwing your money away. Analyzing the key information contained in Cardiol Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Cardiol Therapeutics Key Financial Ratios
Cardiol Therapeutics' financial ratios allow both analysts and investors to convert raw data from Cardiol Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Cardiol Therapeutics over time and compare it to other companies across industries.
Comparative valuation techniques use various fundamental indicators to help in determining Cardiol Therapeutics's current stock value. Our valuation model uses many indicators to compare Cardiol Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cardiol Therapeutics competition to find correlations between indicators driving Cardiol Therapeutics's intrinsic value. More Info.
Cardiol Therapeutics Class is rated fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Cardiol Therapeutics' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Cardiol Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cardiol Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.
Cardiol Therapeutics Systematic Risk
Cardiol Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cardiol Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Cardiol Therapeutics correlated with the market. If Beta is less than 0 Cardiol Therapeutics generally moves in the opposite direction as compared to the market. If Cardiol Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cardiol Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cardiol Therapeutics is generally in the same direction as the market. If Beta > 1 Cardiol Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Cardiol Therapeutics Class Total Assets Over Time
Today, most investors in Cardiol Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cardiol Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cardiol Therapeutics growth as a starting point in their analysis.
Cardiol Therapeutics March 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cardiol Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cardiol Therapeutics Class. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cardiol Therapeutics Class based on widely used predictive technical indicators. In general, we focus on analyzing Cardiol Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cardiol Therapeutics's daily price indicators and compare them against related drivers.
When determining whether Cardiol Therapeutics is a strong investment it is important to analyze Cardiol Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiol Therapeutics' future performance. For an informed investment choice regarding Cardiol Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.